TABLE OF CONTENTS
Volume 23, Issue 8 (August 2009)
Editorial
Iron chelation therapy in myelodysplastic syndrome — Cui bono? FREE
A Tefferi and R M Stone
Leukemia 23: 1373; doi:10.1038/leu.2009.39
Concise Review
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia FREE
P J Real and A A Ferrando
Leukemia 23: 1374-1377; advance online publication, April 9, 2009; doi:10.1038/leu.2009.75
Original Articles
Molecular Targets for Therapy
The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation
M Abraham, K Beider, H Wald, I D Weiss, D Zipori, E Galun, A Nagler, O Eizenberg and A Peled
Leukemia 23: 1378-1388; advance online publication, March 26, 2009; doi:10.1038/leu.2009.56
Therapy
A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
B ten Cate, E Bremer, M de Bruyn, T Bijma, D Samplonius, M Schwemmlein, G Huls, G Fey and W Helfrich
Leukemia 23: 1389-1397; advance online publication, March 5, 2009; doi:10.1038/leu.2009.34
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S Mustjoki, M Ekblom, T P Arstila, I Dybedal, P K Epling-Burnette, F Guilhot, H Hjorth-Hansen, M Höglund, P Kovanen, T Laurinolli, J Liesveld, R Paquette, J Pinilla-Ibarz, A Rauhala, N Shah, B Simonsson, M Sinisalo, J L Steegmann, L Stenke and K Porkka
Leukemia 23: 1398-1405; advance online publication, March 19, 2009; doi:10.1038/leu.2009.46
Acute Leukemias
Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1
S Jeha, D Pei, S C Raimondi, M Onciu, D Campana, C Cheng, J T Sandlund, R C Ribeiro, J E Rubnitz, S C Howard, J R Downing, W E Evans, M V Relling and C-H Pui
Leukemia 23: 1406-1409; advance online publication, March 12, 2009; doi:10.1038/leu.2009.42
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial
J E Rubnitz, K R Crews, S Pounds, S Yang, D Campana, V V Gandhi, S C Raimondi, J R Downing, B I Razzouk, C-H Pui and R C Ribeiro
Leukemia 23: 1410-1416; advance online publication, February 26, 2009; doi:10.1038/leu.2009.30
The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group
A Larson Gedman, Q Chen, S Kugel Desmoulin, Y Ge, K LaFiura, C L Haska, C Cherian, M Devidas, S B Linda, J W Taub and L H Matherly
Leukemia 23: 1417-1425; advance online publication, April 2, 2009; doi:10.1038/leu.2009.64
Chronic Myeloproliferative Neoplasias
RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation
M-C Kuo, D-C Liang, C-F Huang, Y-S Shih, J-H Wu, T-L Lin and L-Y Shih
Leukemia 23: 1426-1431; advance online publication, March 12, 2009; doi:10.1038/leu.2009.48
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway
R Naughton, C Quiney, S D Turner and T G Cotter
Leukemia 23: 1432-1440; advance online publication, March 19, 2009; doi:10.1038/leu.2009.49
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients FREE
A Pardanani, T Lasho, G Smith, C J Burns, E Fantino and A Tefferi
Leukemia 23: 1441-1445; advance online publication, March 19, 2009; doi:10.1038/leu.2009.50
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice
Y Chen, Y Hu, S Michaels, D Segal, D Brown and S Li
Leukemia 23: 1446-1454; advance online publication, March 26, 2009; doi:10.1038/leu.2009.52
Stem Cells
Defective engraftment of C3aR-/- hematopoietic stem progenitor cells shows a novel role of the C3a–C3aR axis in bone marrow homing
M Wysoczynski, R Reca, H Lee, W Wu, J Ratajczak and M Z Ratajczak
Leukemia 23: 1455-1461; advance online publication, April 9, 2009; doi:10.1038/leu.2009.73
PML–RAR
initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors
S Wojiski, F C Guibal, T Kindler, B H Lee, J L Jesneck, A Fabian, D G Tenen and D G Gilliland
Leukemia 23: 1462-1471; advance online publication, March 26, 2009; doi:10.1038/leu.2009.63
Minimal Residual Disease
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study
A M Willasch, B Gruhn, T Coliva, M Kalinova, G Schneider, H Kreyenberg, D Steinbach, G Weber, I H I M Hollink, C M Zwaan, A Biondi, V H J van der Velden, D Reinhardt, G Cazzaniga, P Bader and J Trka on behalf of the European Study Group on WT1 Expression in Childhood AML. Frankfurt, Jena (Germany), Monza (Italy), Prague (Czech Republic)
Leukemia 23: 1472-1479; advance online publication, March 26, 2009; doi:10.1038/leu.2009.51
Normal Hemopoiesis
The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domains
J A Marteijn, L T van der Meer, J J Smit, S M Noordermeer, W Wissink, P Jansen, H G Swarts, R G Hibbert, T de Witte, T K Sixma, J H Jansen and B A van der Reijden
Leukemia 23: 1480-1489; advance online publication, April 2, 2009; doi:10.1038/leu.2009.57
Oncogenes, Fusion Genes and Tumor Suppressor Genes
New insights to the MLL recombinome of acute leukemias
C Meyer, E Kowarz, J Hofmann, A Renneville, J Zuna, J Trka, R Ben Abdelali, E Macintyre, E De Braekeleer, M De Braekeleer, E Delabesse, M P de Oliveira, H Cavé, E Clappier, J J M van Dongen, B V Balgobind, M M van den Heuvel-Eibrink, H B Beverloo, R Panzer-Grümayer, A Teigler-Schlegel, J Harbott, E Kjeldsen, S Schnittger, U Koehl, B Gruhn, O Heidenreich, L C Chan, S F Yip, M Krzywinski, C Eckert, A Möricke, M Schrappe, C N Alonso, B W Schäfer, J Krauter, D A Lee, U zur Stadt, G Te Kronnie, R Sutton, S Izraeli, L Trakhtenbrot, L Lo Nigro, G Tsaur, L Fechina, T Szczepanski, S Strehl, D Ilencikova, M Molkentin, T Burmeister, T Dingermann, T Klingebiel and R Marschalek
Leukemia 23: 1490-1499; advance online publication, March 5, 2009; doi:10.1038/leu.2009.33
Apoptosis
Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells
P Gamas, S Marchetti, A Puissant, S Grosso, A Jacquel, P Colosetti, J-M Pasquet, F-X Mahon, J-P Cassuto and P Auberger
Leukemia 23: 1500-1506; advance online publication, April 2, 2009; doi:10.1038/leu.2009.60
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis
Q-L Zhang, L Wang, Y-W Zhang, X-X Jiang, F Yang, W-L Wu, A Janin, Z Chen, Z-X Shen, S-J Chen and W-L Zhao
Leukemia 23: 1507-1514; advance online publication, March 12, 2009; doi:10.1038/leu.2009.41
Myeloma
Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors
M Garayoa, J L Garcia, C Santamaria, A Garcia-Gomez, J F Blanco, A Pandiella, J M Hernández, F M Sanchez-Guijo, M-C del Cañizo, N C Gutiérrez and J F San Miguel
Leukemia 23: 1515-1527; advance online publication, April 9, 2009; doi:10.1038/leu.2009.65
Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant
P N Hari, M-J Zhang, V Roy, W S Pérez, A Bashey, L B To, G Elfenbein, C O Freytes, R P Gale, J Gibson, R A Kyle, H M Lazarus, P L McCarthy, G A Milone, S Pavlovsky, D E Reece, G Schiller, J Vela-Ojeda, D Weisdorf and D Vesole
Leukemia 23: 1528-1534; advance online publication, March 26, 2009; doi:10.1038/leu.2009.61
